Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you
CLVT Shareholders Click Here: https://www.zlk.com/pslra-1/clarivate-plc-loss-submission-form?prid=24776&wire=1
SLI Shareholders Click Here: https://www.zlk.com/pslra-1/standard-lithium-ltd-loss-submission-form?prid=24776&wire=1
FB Shareholders Click Here: https://www.zlk.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=24776&wire=1
* ADDITIONAL INFORMATION BELOW *
CLVT Lawsuit on behalf of: investors who purchased November 10, 2020 – February 2, 2022
Lead Plaintiff Deadline : March 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/clarivate-plc-loss-submission-form?prid=24776&wire=1
According to the filed complaint, during the class period, Clarivate Plc made materially false and/or misleading statements and/or failed to disclose that: (i) Clarivate maintained defective disclosure controls and procedures as a result of a material weakness in its internal control over financial reporting; (ii) the foregoing material weakness was not limited to how the Company accounted for warrants; (iii) as a result, Clarivate failed to properly account for an equity plan included in its acquisition of CPA Global, a global leader in Intellectual Property software and tech-enabled services; (iv) accordingly, the Company was reasonably likely to restate one or more of its previously issued financial statements following its acquisition of CPA Global; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
SLI Lawsuit on behalf of: investors who purchased May 19, 2020 – November 17, 2021
Lead Plaintiff Deadline : March 28, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/standard-lithium-ltd-loss-submission-form?prid=24776&wire=1
According to the filed complaint, during the class period, Standard Lithium Ltd. made materially false and/or misleading statements and/or failed to disclose that: (i) the LiSTR Direct Lithium Extraction technology’s extraction recovery efficiencies were overstated; (ii) accordingly, the Company’s final product lithium recovery percentage at the Demonstration Plant would not be as high as the Company had represented to investors; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
FB Lawsuit on behalf of: investors who purchased March 2, 2021 – February 2, 2022
Lead Plaintiff Deadline : May 9, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=24776&wire=1
According to the filed complaint, during the class period, Meta Platforms, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
News Provided by ACCESSWIRE IA via QuoteMedia
NetworkNewsAudio DGTL Holdings Inc. (TSX.V: DGTL) (OTCQB: DGTHF) announces the availability of a broadcast titled, “Parabolic Growth Curve in Digital Media, Martech Sector Has Tech SPACS and Small Caps Booming.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please visit: https://nnw.fm/Ht8ys
Companies devote much more advertising and marketing capital to social media and influencer spending than traditional broadcast and print media, etc. To that end, out of an estimated $572 billion in total global ad spend in 2020, $291.7 billion was allocated to digital ads. Social ad spending rose 20% year over year to $43 billion, while social media influencer/content marketing — a hot new trend — jumped 50% to $9.7 billion last year and is expected to double again in the coming 12 to 18 months.
These trends play to the strengths of tech accelerator DGTL Holdings Inc. (TSX.V: DGTL) (OTCQB: DGTHF) , as the company builds a portfolio of B2B enterprise SaaS in the digital media, martech, adtech and e-commerce sectors. Last year, DGTL (an acronym for Digital Growth Technologies and Licensing) acquired Hashoff, an enterprise-level, self-service CaaS built on artificial intelligence and machine learning (AI/ML) technology.
About DGTL Holdings Inc.
DGTL Holdings acquires and accelerates transformative digital media, marketing and advertising software technologies powered by artificial intelligence (“AI”). DGTL (i.e. Digital Growth Technologies and Licensing) specializes in accelerating fully commercialized enterprise-level SaaS (software-as-a-service) companies in the sectors of content, analytics and distribution, via a blend of unique capitalization structures. DGTL Holdings Inc. is traded on the Toronto Venture Exchange as “DGTL,” the OTCQB exchange as “DGTHF” and the Frankfurt Stock Exchange as “A2QB0L.”
For more information, visit www.DGTLInc.com/Investors .
NOTE TO INVESTORS: The latest news and updates relating to DGTHF are available in the company’s newsroom at https://ibn.fm/DGTHF
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
News Provided by GlobeNewswire via QuoteMedia
Lexaria Bioscience Corp. (OTCQX:LXRP, CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces the following strategic update. (This is a shortened version of the full Strategic Update from the CEO. For the full version, please go to www.lexariabioscience.com/news/)
“Lexaria’s brightest days lie in the future, not in the past,” said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. Lexaria achieved many things during 2019 – indeed, management feels that it achieved virtually all that it had set out to accomplish and it was its best year ever from an operational perspective. Market forces caused a retreat in valuations across the sector to the point where Mr. Bunka commented that “It is my own opinion that Lexaria shares are dramatically undervalued – more so today than at any time in our history.”
Not many small-cap or nano-cap companies ever manage to achieve any kind of official relationship with Fortune 500-style companies. Some of the largest corporations in the world have asked about our technology and we knew from those discussions that our DehydraTECHTM technology had the ability to deliver more important results than simply getting cannabis users to feel their desired effects quickly. While it will take additional time to design and gain approval for next-generation nicotine products both within America and around the world, Lexaria is highly confident that it will do so. Lexaria is proud to have attracted Altria Group, Inc, owner of both combustible and non-combustible tobacco companies which have been the undisputed market leaders in the U.S. tobacco industry for decades.
During 2019 we finalized a new contractual relationship with a GMP-certified, FDA registered production company to get enhanced DehydraTECH powders to market in the US with current capacity of roughly 200,000 servings per day which can be increased to 400,000 servings per day within the same facility, as needed. Lexaria is experiencing strong demand from many companies requesting pre-processed DehydraTECH-enhanced bulk powders for their specific product lines and with this facility, we can meet that demand.
Lexaria’s IP strategy continues to pay dividends, as we received our first ever patents to use DehydraTECH with cannabinoids for treatment of health conditions including Alzheimer’s, Schizophrenia, Parkinson’s, and heart disease, in August 2019 in Australia. Lexaria is utilizing the procedural tools offered by the international Patent Prosecution Highway, to try to gain fast-track patent status for these same conditions in the US during 2020. Strengthened patent claims related to health conditions better empower Lexaria to build relationships in the pharmaceutical industry; one of our goals for 2020.
As we begin Q1 of 2020, we are seeing signs of increases in revenue to Lexaria that should be sustainable and supportive of future growth. One of our existing US clients is embarking on an aggressive growth strategy from their home state to several additional states within the next year. Another existing US client is in the next 90 days launching their bottled beverage with CBD and DehydraTECH technology within, generating first-ever revenue for Lexaria during Q1.
With existing clients, Lexaria expects to more than double its entire 2019 revenue. With a rich pipeline of prospective additional clients onboarding during 2020, we expect to see further gains in revenue. Comfort with our working relationships with existing corporate clients enables us to say we expect strong, sustainable revenue growth in 2020 and beyond.
One objective for the Company during 2020 is to dramatically alter our capital markets strategy. During the last six months Lexaria has met with a number of Wall Street investment banking firms as we devise our long-term capital markets strategy. Lexaria expects to pursue a strategy during 2020 to qualify for listing on a nationally-recognized US exchange, allowing a dramatically larger audience of investors to consider Lexaria’s attributes and opening a path to increased quantity and quality of strategic opportunities.
To see the full Strategic Update, please go to www.lexariabioscience.com/news/
About Lexaria
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Chris Bunka, CEO
(250) 765-6424
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
SOURCE
Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.
Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated.
Mr. Quigley is a 20-year Consumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing. In his time at Altria, Mr. Quigley spearheaded harm reduction strategies and worked to deliver results by creating change in the tobacco business in North America. Mr. Quigley has launched dozens of new products, created consumer-focused innovation strategies, and built businesses and cultures that deliver results.
Mr. Quigley formed Green Sky Strategy with other cannabis community leaders following four years of investing and strategic advisory roles to create the first cannabis strategy team that combines deep cannabis industry and consumer experience with proven Fortune 500 strategic thinking. A graduate of the University of New Hampshire, Mr. Quigley serves on the board of the Science Museum of Virginia Foundation and on the board of trustees of the Virginia Foundation for Independent Colleges.
“Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies and we welcome Brian’s expertise,” said Chris Bunka, Chairman of the Board of Lexaria Bioscience Corp. “His years of regulatory, product launch, and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”
“I am thrilled to be joining the already strong team at Lexaria Bioscience. From my first engagement with Chris, it was clear to me that Lexaria and its leadership team is positioned to create change through innovation in both the Cannabis and Nicotine space. It is an honor to join this team after forging such a strong partnership with them during my time with Altria.“
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.
Source: www.accesswire.com
Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed.
Lexaria’s new cannabis R&D license is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECHTM infusions as well as including two different methodologies by which the Company can create nano-sized molecules when deemed beneficial and is currently operational.
Previously, Lexaria had contracted with third-party agencies and institutions to conduct much of its R&D with controlled substances. The new lab, where Lexaria recently welcomed a new full-time PhD Research Scientist on staff, will significantly accelerate many R&D programs already designed but not yet implemented.
Lexaria’s state-of-the-art laboratory will for R&D purposes be producing and evaluating topical creams and lotions and many varieties of orally-ingested product formats for delivery performance characteristics of active ingredients including THC; CBD; NSAID’s such as ibuprofen; PDE5-inhibitors such as those used in Viagra; nicotine; and, other molecules of interest.
“Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company’s history,” said John Docherty, President and Chief Scientist of Lexaria. “This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada’s licensed cannabis companies.”
The Company plans to provide R&D updates often but cautions that it often must keep proprietary information or discoveries confidential for reasons of patent pursuit.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.
Source: www.accesswire.com
Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp., to provide Lexaria’s patented DehydraTECHTM technology to Universal Hemp LLC, a B2B manufacturing company of high-performing hemp-derived bulk ingredients to the nutraceutical and consumer packaged goods industries, for utilization into many CBD-based food ingredients to be produced and sold across the USA immediately, and in Canada when regulations permit.
Competitive financial details including royalty rates remain confidential and undisclosed although the companies have agreed to disclose minimum payments over the life of the agreement of US$3,750,000.
“We are very excited about signing this licensing agreement with Lexaria Bioscience to bring to market Lexaria’s highly effective delivery system which makes cannabidiol or hemp-derived CBD readily available in the human body,” said Chad Kahunahana, CEO and Founder of Universal Hemp. “Lexaria’s unique technology was developed over many years for specified applications and is now, for the first time, being applied to CBD at scale and available for general use. We anticipate our SuperBio Infusion line of ingredients will become the industry leader for CBD-infused health and beauty, food and beverage, wellness, athletic and other products where maximum performance is vital. In terms of bioavailability, shelf stability and taste this is the best performing technology in the market, hands down. Our corporate customers cannot wait to put our water-soluble solution into their products!” added Kahunahana.
The DehydraTECH-enabled food ingredients are protected under Lexaria’s many existing US-granted patents and may include forms such as CBD-infused wheat or corn flour, gum Arabic, whey protein, green tea, tapioca starch and many others including forms suitable for beverage and dietary supplement formulation.
“We are pleased to announce our new licensee Universal Hemp whose well respected presence in the hemp industry will enable our patented technology to have widespread use and distribution in high-performance products providing precision dosing, maximum strength, and rapid uptake,” said Chris Bunka, Lexaria Bioscience CEO.
Universal Hemp plans to make its CBD-infused bulk food ingredients available throughout the USA immediately, and in Canada when regulations permit.
About the Market
According to industry research, U.S. sales of CBD are expected to grow 10x to an estimated $20 Billion by 2024. Edibles such as food, drinks and nutritional supplements are the largest category for CBD products. With the passage of the 2018 Farm Bill which included the Hemp Farming Act of 2018, all parts of the industrial hemp plant, including CBD and other hemp-derived cannabinoids, can be sold legally across the United States.
About Universal Hemp
Universal Hemp LLC is a leading manufacturer of hemp-based raw ingredients and CBD derivatives for innovative brands. The company plans to make its CBD-infused bulk food ingredients available across the USA immediately and in Canada when regulations permit. The company has offices in Boulder, Colorado; Brooklyn, New York; and Honolulu, Hawaii. Universal Hemp is currently in discussions with blue-chip investors to raise a significant funding round to build the largest cGMP manufacturing facility in North America for full-spectrum, highly-bioavailable bulk ingestible CBD-based ingredients to supply the rapidly growing needs of its customers. www.universalhemp.co
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250)765-6424 Ext 202
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
For Universal Hemp Information Contact:
Neshama Abraham, Communications Manager
(303) 413-8252 or neshama@universalhemp.com
www.UniversalHemp.co
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that Universal Hemp Corp. will achieve the goals of its business plan and be capable of fully executing its relationship with the Company. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBDTM, DehydraTECHTM technology and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.
Source: www.accesswire.com
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .
Ericsson (NASDAQ: ERIC )
Class Period: April 27, 2017 – February 25, 2022
Lead Plaintiff Deadline: May 2, 2022
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Ericsson overstated the extent to which it had reformed its business practices to eliminate the use of bribes to secure business in foreign countries; (2) Ericsson had paid bribes to the terrorist group the Islamic State in Iraq and Syria to gain access to certain transport routes in Iraq; (3) accordingly, the Company’s revenues derived from its operations in Iraq were, in at least substantial part, derived from unlawful conduct and thus unsustainable; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
C3.ai, Inc. (NYSE: AI )
Class Period: December 9, 2020 – February 15, 2022
Lead Plaintiff Deadline: May 3, 2022
Shareholders with $50,000 losses or more are encouraged to contact the firm
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) C3.ai’s partnership with Baker Hughes was deteriorating; (2) C3.ai was employing a flawed accounting methodology to conceal the deterioration of its Baker Hughes partnership; (3) C3.ai faced challenges in product adoption and significant salesforce turnover; (4) the Company overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its market growth, and the scale of alliances with its major business partners; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
Rivian Automotive, Inc. (NASDAQ: RIVN )
Class Period: November 2021 IPO
Lead Plaintiff Deadline: May 6, 2022
Shareholders with $25,000 losses or more are encouraged to contact the firm.
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose: (1) that Rivian had underpriced the R1T and R1S to such a degree that Rivian would be forced to raise prices shortly after the IPO; (2) the potential for significant reputational damage and cancellation of fully refundable preorders for the R1T and R1S that would result from Company’s need to address its underpriced EVs by raising prices shortly after the IPO; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Meta Platforms, Inc. (NASDAQ: FB )
Class Period: March 2, 2021 – February 2, 2022
Lead Plaintiff Deadline: May 9, 2022
Shareholders with $100,000 losses or more are encouraged to contact the firm.
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com , or visit our website at www.howardsmithlaw.com .
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
News Provided by GlobeNewswire via QuoteMedia
Expanded network of specialist partners now offering BlackBerry’s single-tool solution to help developers, manufacturers and regulators analyze and detect threats in complex embedded systems
BlackBerry Limited (NYSE: BB; TSX: BB) today announced 13 channel partners (Distributors & Value Added Integrators) that will offer BlackBerry® Jarvis® 2.0 to companies that build secure, mission-critical systems in APAC. Whether in transportation, medical equipment or on the factory floor BlackBerry Jarvis is key for industries that must adhere to strict regulations while managing complex supply chains and the escalating risk of security attacks on cyber and physical systems.
BlackBerry Jarvis is a binary software composition analysis (SCA) and security testing tool, designed to detect and list open-source software and software licenses within embedded systems, as well as cybersecurity vulnerabilities and exposures. It performs a thorough scan of the software binary and produces a software bill of materials (SBOM), offering deep actionable insights in a fraction of the time it takes for security professionals to manually perform these tasks. Embedded software developers use BlackBerry Jarvis to demonstrate compliance to specific security standards and harden their systems to make them more resilient. Regulators can also use the tool to enforce compliance, verifying security claims by manufacturers and suppliers.
” Asia Pacific is at a tipping point in how it protects infrastructure and industries against growing IoT security threats as digital automation continues to advance,” said Dhiraj Handa , VP, Asia Pacific , BlackBerry QNX. “As a leader in mission-critical solutions, BlackBerry QNX is excited to enable so many ecosystem partners to deliver BlackBerry Jarvis across more sectors, offering rapid, trusted intelligence to companies, developers and regulators that need to protect IP, address compliance issues and deploy security resources where they are needed most.”
The BlackBerry Jarvis partners include UPS Technology (Korea), KMS Technology Inc. (Korea), RT Solutions Inc. (Korea), Strategic Innovation Business Group, Macnica, Inc. ( Japan ), Hitachi Industry & Control Solutions, Ltd. ( Japan ), ISB Corporation ( Japan ), Nexty Electronics Corporation ( Japan ), SC Automotive Engineering Co., Ltd. ( Japan ), Gopalam Embedded Systems Pte Ltd ( India ), AdvanTrak Technologies Private Limited ( India ), Thunder Software Technology Co., Ltd. ( China ), Mcloudware Technology Co., Limited ( Taiwan ), and Nanjing Leading R&D Information Technology Limited ( China ).
BlackBerry’s partner news follows a spate of high-profile cyberattacks on critical infrastructure as networks and legacy systems are increasingly exposed by the convergence of information technology (IT) and operational technology (OT). In response, nations are introducing multiple safety and security standards for industries such as automotive, medical, industrial automation and rail. This shows no sign of slowing, with the Ponemon Institute 1 finding that 9 out of 10 companies adopting IoT expect to experience a breach or attack caused by unsecured IoT devices in the next two years.
Earlier this year, BlackBerry Jarvis was also recognized as “Best in Breed” among leading binary analysis solutions by an Internal Research & Development project (IRAD). The analysis was conducted on behalf of the United States Department of Defense (DoD) by The Aerospace Corporation , and recommends the most proficient binary analysis solutions on the market for embedded software, citing BlackBerry Jarvis as the most promising and robust after a rigorous assessment of all the key players.
For more information on BlackBerry Jarvis please visit BlackBerry.com/Jarvis . To learn more about BlackBerry QNX IoT partners, please visit https://blackberry.qnx.com/en/partners/qnx-partner-directory .
About BlackBerry
BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including 195M vehicles. Based in Waterloo, Ontario , the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety, and data privacy solutions, and is a leader in the areas of endpoint security, endpoint management, encryption, and embedded systems. BlackBerry’s vision is clear – to secure a connected future you can trust.
BlackBerry. Intelligent Security. Everywhere.
For more information, visit BlackBerry.com and follow @BlackBerry.
Trademarks, including but not limited to BLACKBERRY and EMBLEM Design are the trademarks or registered trademarks of BlackBerry Limited, and the exclusive rights to such trademarks are expressly reserved. All other trademarks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.
Media Contacts:
BlackBerry Media Relations
+1 (519) 597-7273
mediarelations@BlackBerry.com
1 “A New Roadmap for Third Party IoT Risk Management – Ponemon Institute ( June 3, 2020 )
View original content: https://www.prnewswire.com/news-releases/asia-pacific-channel-partners-select-blackberry-jarvis-to-secure-iot-software-301506275.html
SOURCE BlackBerry Limited
News Provided by PR Newswire via QuoteMedia
The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery
Butterfly Network, Inc. f/k/a Longview Acquisition Corp. (NYSE:BFLY)
This lawsuit is one behalf of: (a) all persons or entities that purchased or otherwise acquired Butterfly securities between February 16, 2021 and November 15, 2021, both dates inclusive and/or (b) all holders of Butterfly common stock as of the record date for the special meeting of shareholders held on February 12, 2021 to consider approval of the merger between Longview Acquisition Corp. and Butterfly.
A class action has commenced on behalf of certain shareholders in Butterfly Network, Inc f/k/a Longview Acquisition Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Butterfly had overstated its post-merger business and financial prospects; (ii) notwithstanding the ongoing COVID-19 pandemic, Butterfly’s financial projections failed to take into account the pandemic’s broad consequences, which included healthcare logistical challenges, and medical personnel fatigue; (iii) accordingly, Butterfly’s gross margin levels and revenue projections were less sustainable than the Company had represented; (iv) all the foregoing was reasonably likely to have a material negative impact on Butterfly’s business and financial condition; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/butterfly-network-inc-f-k-a-longview-acquisition-corp-loss-submission-form/?id=24908&from=1
Affirm Holdings, Inc. (NASDAQ:AFRM)
This lawsuit is on behalf of all investors who purchased or otherwise acquired Affirm Holdings, Inc. securities on February 10, 2022 after the Company sent a Tweet concerning its Second Quarter 2022 financial results at approximately 1:15 p.m. EST.
A class action has commenced on behalf of certain shareholders in Affirm Holdings, Inc. According to the filed complaint, on February 10, 2022 at approximately 1:15 p.m., Affirm issued a Tweet from its official account in which the Company disclosed certain metrics from its second quarter 2022 financial results. The Tweet, which was published prior to the Company’s planned release of its financial results, portrayed a highly successful quarter, which included an increase in revenue of 77%. This caused Affirm’s share price to spike nearly 10% in intra-day trading. The Tweet was materially misleading, in that it omitted to disclose the full details of Affirm’s second quarter financial results. Affirm deleted the Tweet and released its full second quarter financial results ahead of schedule. The full financial results were lackluster – with the Company posting a loss of $0.57 per share, compared with analyst expectations of $0.37 per share.
Shareholders may find more information at https://securitiesclasslaw.com/securities/affirm-holdings-inc-loss-submission-form/?id=24908&from=1
Meta Platforms, Inc. (NASDAQ:FB)
Investors Affected : March 2, 2021 – February 2, 2022
A class action has commenced on behalf of certain shareholders in Meta Platforms, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
Shareholders may find more information at https://securitiesclasslaw.com/securities/meta-platforms-inc-loss-submission-form/?id=24908&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE : The Gross Law Firm
News Provided by ACCESSWIRE IA via QuoteMedia
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you
Butterfly Network, Inc. f/k/a Longview Acquisition Corp. (NYSE:BFLY)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/butterfly-network-inc-f-k-a-longview-acquisition-corp-loss-submission-form?prid=24897&wire=1
Lead Plaintiff Deadline: April 18, 2022
This lawsuit is one behalf of: (a) all persons or entities that purchased or otherwise acquired Butterfly securities between February 16, 2021 and November 15, 2021, both dates inclusive and/or (b) all holders of Butterfly common stock as of the record date for the special meeting of shareholders held on February 12, 2021 to consider approval of the merger between Longview Acquisition Corp. and Butterfly.
Allegations against BFLY include that: (i) Butterfly had overstated its post-merger business and financial prospects; (ii) notwithstanding the ongoing COVID-19 pandemic, Butterfly’s financial projections failed to take into account the pandemic’s broad consequences, which included healthcare logistical challenges, and medical personnel fatigue; (iii) accordingly, Butterfly’s gross margin levels and revenue projections were less sustainable than the Company had represented; (iv) all the foregoing was reasonably likely to have a material negative impact on Butterfly’s business and financial condition; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Rivian Automotive, Inc. (NASDAQ:RIVN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/rivian-automotive-inc-loss-submission-form?prid=24897&wire=1
Lead Plaintiff Deadline: May 6, 2022
This lawsuit is on behalf of investors that purchased or otherwise acquired Rivian common stock pursuant and/or traceable to Rivian’s initial public offering on November 10, 2021.
Documents issued in connection with the initial public offering contained representations that were materially inaccurate, misleading, and/or incomplete because they failed to disclose, among other things, that the R1T electric pickup truck and R1S electric SUV were underpriced to such a degree that Rivian would have to raise prices shortly after the IPO and that these price increases would tarnish Rivian’s reputation as a trustworthy and transparent company and would put a significant number of the existing backlog of 55,400 preorders, along with future preorders, in jeopardy of cancellation.
Meta Platforms, Inc. (NASDAQ:FB)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=24897&wire=1
Lead Plaintiff Deadline: May 9, 2022
Class Period: March 2, 2021 – February 2, 2022
Allegations against FB include that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE : The Law Offices of Vincent Wong
News Provided by ACCESSWIRE IA via QuoteMedia
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Meta Platforms, Inc. (NASDAQ: FB).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/meta-platforms-inc-loss-submission-form/?id=24834&from=4
The lawsuit seeks to recover losses for shareholders who purchased Meta Platforms, Inc. between March 2, 2021 and February 2, 2022.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until May 9, 2022 to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
According to a filed complaint, Meta Platforms, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original content: https://www.prnewswire.com/news-releases/fb-shareholder-alert-jakubowitz-law-reminds-meta-platforms-inc-shareholders-of-a-lead-plaintiff-deadline-of-may-9-2022-301505383.html
SOURCE Jakubowitz Law
News Provided by PR Newswire via QuoteMedia
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
